← All trials
NCT06752356
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2025
- Primary completion
- Dec 20, 2027
- Completion date
- Dec 27, 2027
- First posted
- Dec 30, 2024
- Last posted
- Oct 14, 2025
- Enrollment
- 161
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Kedrion SpALead sponsor
- Kedrion SpAOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.